September 5, 2006--Under the terms of the agreement, Infinity will maintain responsibility for discovery, preclinical development, and initial proof-of-concept trials in humans. The two companies will split the cost of clinical development and initial regulatory approval; MedImmune will then take the lead on worldwide regulatory approval and marketing. The companies also plan to share any profits equally.

The Hsp90 and Hedgehog programs are Infinity's most advanced drug development programs, with the lead Hsp90 compound, IPI-504, already in two Phase I clinical trials. "We have very compelling preclinical data for both of those programs against a very broad range of tumor types," said Adelene Perkins, Infinity's executive vice president and chief business officer. "We are now making the decision of the number of different clinical trials that we need to go into and, strategically, a partner can really help us ensure that we are fully able to evaluate these programs." 

Read the entire article.